| Adisyn Ltd (AI1) ORDINARY FULLY PAID |
Information Technology |
$229 |
Half Year Financial Report and Appendix 4D
|
27 Feb 2026 12:17PM |
$0.052 |
$0.220 |
risen by
323.08%
|
|
AI1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Loss for the half-year was $4,564,254.
- Total revenue for the half-year was $103,754.
- Adisyn Services business unit is held for sale.
- Significant technical progress with the ALD system for graphene-based interconnects.
- The company has identified opportunities in the global semiconductor industry.
- No dividends were paid or declared during the period.
- Going concern basis is maintained with the directors' confidence in the company's financial stability.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Great Dirt Resources Limited (GR8) ORDINARY FULLY PAID |
Materials |
$39 |
Application for quotation of securities - GR8
|
27 Feb 2026 12:16PM |
$0.623 |
$0.800 |
risen by
28.51%
|
|
| DataDot Technology Limited (DDT) ORDINARY FULLY PAID |
Consumer Discretionary |
$4 |
Application for quotation of securities - DDT
|
27 Feb 2026 12:11PM |
$0.005 |
$0.003 |
fallen by
40%
|
|
| New Murchison Gold Limited (NMG) ORDINARY FULLY PAID |
Materials |
$500 |
Chairman's Address to Annual General Meeting
|
27 Feb 2026 12:09PM |
$0.066 |
$0.046 |
fallen by
30.30%
|
|
| Thrive Tribe Technologies Limited (1TT) ORDINARY FULLY PAID |
Information Technology |
$2 |
Appendix 4D and Half Year Reports 31 Dec 2025
|
27 Feb 2026 12:07PM |
$0.001 |
$0.001 |
fallen by
0%
|
|
1TT - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue decreased by 26.6% to $49,372.
- Loss after tax increased by 45.4% to $1,806,105.
- No dividends were declared or paid.
- Focus on developing MyTribe app and Thrive Tribe Home Base.
- Impairment of $947,493 recognized for MyTribe app development.
- Cash reserves stood at $100,936.
- Directors confident in company's future despite financial challenges.
- Strategic focus on scaling performance marketing and influencer network.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| SEEK Limited (SEK) ORDINARY FULLY PAID |
Communication Services |
$4,772 |
Appendix 3Y - Leigh Jasper
|
27 Feb 2026 12:05PM |
$16.285 |
$13.360 |
fallen by
17.96%
|
|
| ECS Botanics Holdings Ltd (ECS) ORDINARY FULLY PAID |
Health Care |
$10 |
H1 FY26 Results-Return to Profitability & Positive Cashflow
|
27 Feb 2026 12:02PM |
$0.006 |
$0.006 |
fallen by
0%
|
|
ECS - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 16.5% to $11.34 million.
- Profit before tax of $0.04 million, reversing a previous loss.
- EBITDA improved to $0.8 million.
- Two consecutive quarters of positive operating cash flow.
- Branded products account for 60% of total revenue.
- Completed infrastructure expansions for year-round production.
- Launch preparations for new women's health brand AVANI AVA.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ECS Botanics Holdings Ltd (ECS) ORDINARY FULLY PAID |
Health Care |
$10 |
Half Yearly Report and Accounts
|
27 Feb 2026 12:01PM |
$0.006 |
$0.006 |
fallen by
0%
|
|
ECS - Price-sensitive ASX Announcement
Full Release
Key Points
- ECS Botanics Holdings Ltd reported a 16.5% increase in revenue for the half year ended 31 December 2025.
- The company achieved two consecutive quarters of positive operating cash flow, reflecting improved operational efficiency.
- ECS received a $118,000 grant to support expansion into the production of live rosin cartridges.
- Branded business-to-consumer (B2C) products accounted for 60% of total revenue, marking a shift from wholesale to brand-led operations.
- ECS launched a women’s health brand, AVANI AVA, targeting a growing segment of the medicinal cannabis market.
- The company faced ongoing price compression in dried flower due to import competition.
- Net tangible assets per security decreased to 2.06 cents from 2.61 cents a year prior.
- ECS has a diversified branded portfolio and is progressing international initiatives, including expansion in Europe.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tivan Limited (TVN) ORDINARY FULLY PAID |
Materials |
$647 |
Half Year Accounts
|
27 Feb 2026 11:55AM |
$0.435 |
$0.285 |
fallen by
34.48%
|
|
| Australian Clinical Labs Limited (ACL) ORDINARY FULLY PAID |
Health Care |
$356 |
Notification of cessation of securities - ACL
|
27 Feb 2026 11:54AM |
$2.250 |
$1.895 |
fallen by
15.78%
|
|
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$1,617 |
Investor presentation, 27 February 2026
|
27 Feb 2026 11:54AM |
$13.480 |
$12.790 |
fallen by
5.12%
|
|
| Aeris Environmental Ltd (AEI) ORDINARY FULLY PAID |
Industrials |
$9 |
Change of Directors' Interest Notices - MS & SK
|
27 Feb 2026 11:53AM |
$0.043 |
$0.038 |
fallen by
11.63%
|
|
| De.mem Limited (DEM) ORDINARY FULLY PAID |
Utilities |
$24 |
DEM Investor Presentation - Full Year Results
|
27 Feb 2026 11:52AM |
$0.110 |
$0.075 |
fallen by
32.27%
|
|
DEM - Price-sensitive ASX Announcement
Full Release
Key Points
- Record annual EBITDA and cash receipts in 2025.
- High-margin recurring revenue model with over 90% recurring cash receipts.
- Strong acquisition strategy, including Core Chemicals.
- Expansion into residential water treatment products globally.
- Significant growth in Australian and global markets, particularly in the gold sector.
- Positive cashflow and financial outlook for 2026.
- Advanced proprietary hollow fiber membrane technology.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| De.mem Limited (DEM) ORDINARY FULLY PAID |
Utilities |
$24 |
DEM Record Full Year Results
|
27 Feb 2026 11:51AM |
$0.110 |
$0.075 |
fallen by
32.27%
|
|
DEM - Price-sensitive ASX Announcement
Full Release
Key Points
- First full calendar year of positive adjusted EBITDA at $1.6 million.
- Record revenue at $29.9 million and cash receipts at $32.3 million.
- Achieved 43% gross margins, up from 41% in the previous year.
- Core Chemicals acquisition fully integrated, contributing to future profits.
- Strong balance sheet with $4.0 million in cash and term deposits.
- Continued investment in proprietary technology platform.
- On track for record results in CY 2026.
- Strategic focus on high-margin, recurring revenue segments.
- Expansion into gold mining sector and global water filtration market.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Qualitas Real Estate Income Fund (QRI) ORDINARY UNITS FULLY PAID |
Financials |
$997 |
Distribution Announcement
|
27 Feb 2026 11:50AM |
$1.570 |
$1.580 |
risen by
0.64%
|
|
| Qualitas Real Estate Income Fund (QRI) ORDINARY UNITS FULLY PAID |
Financials |
$997 |
Dividend/Distribution - QRI
|
27 Feb 2026 11:50AM |
$1.570 |
$1.580 |
risen by
0.64%
|
|
| Investigator Silver Limited (IVR) ORDINARY FULLY PAID |
Materials |
$166 |
Paris DFS Confirms Maiden Ore Reserve, Strong Economics
|
27 Feb 2026 11:47AM |
$0.120 |
$0.064 |
fallen by
46.67%
|
|
IVR - Price-sensitive ASX Announcement
Full Release
Key Points
- Paris project to process 13,395 kt of ore with 39,015 kOz of silver produced.
- Projected revenue of A$3.33 billion and operating costs of A$1.204 billion.
- EBITDA estimated at A$2.126 billion with a 64% operating margin.
- High-grade silver ore with an average grade of 91% Ag.
- Capital costs amounting to A$260 million, with A$221 million for processing and infrastructure.
- Sensitivity analysis indicates strong project robustness against price fluctuations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| WAM Active Limited (WAA) ORDINARY FULLY PAID |
Financials |
$149 |
Application for quotation of securities - WAA
|
27 Feb 2026 11:46AM |
$1.015 |
$1.010 |
fallen by
0.49%
|
|
| Sandon Capital Investments Limited (SNC) ORDINARY FULLY PAID |
Financials |
$121 |
Application for quotation of securities - SNC
|
27 Feb 2026 11:46AM |
$0.820 |
$0.780 |
fallen by
4.88%
|
|
| Clime Capital Limited (CAM) ORDINARY FULLY PAID |
Financials |
$100 |
Net Tangible Assets Backing - 26 February 2026
|
27 Feb 2026 11:45AM |
$0.705 |
$0.705 |
fallen by
0%
|
|
| LinQ Minerals Limited (LNQ) ORDINARY FULLY PAID |
Materials |
$38 |
Letter to Shareholders - Annual General Meeting
|
27 Feb 2026 11:45AM |
$0.525 |
$0.415 |
fallen by
20.95%
|
|
| LinQ Minerals Limited (LNQ) ORDINARY FULLY PAID |
Materials |
$38 |
Notice of Annual General Meeting/Proxy Form
|
27 Feb 2026 11:44AM |
$0.525 |
$0.415 |
fallen by
20.95%
|
|
| Transmetro Corporation Limited (TCO) ORDINARY FULLY PAID |
Consumer Discretionary |
$37 |
Half Year Accounts
|
27 Feb 2026 11:42AM |
$2.850 |
$2.780 |
fallen by
2.46%
|
|
TCO - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue increased by 13.9% to $14.8 million.
- Net profit increased by 65.0% to $2.879 million.
- Total assets amounted to $42.056 million.
- Total liabilities were $12.893 million.
- Net assets totaled $29.163 million.
- Net cash increase of $2.542 million.
- Cash and cash equivalents at period end were $12.683 million.
- Compliance with Australian Accounting Standards confirmed.
- Auditors reported no contraventions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Brightstar Resources Limited (BTR) ORDINARY FULLY PAID |
Materials |
$395 |
Half Year Accounts
|
27 Feb 2026 11:38AM |
$0.565 |
$0.360 |
fallen by
36.28%
|
|
| De.mem Limited (DEM) ORDINARY FULLY PAID |
Utilities |
$24 |
2025 Appendix 4E and Annual Report
|
27 Feb 2026 11:36AM |
$0.100 |
$0.075 |
fallen by
25.50%
|
|
DEM - Price-sensitive ASX Announcement
Full Release
Key Points
- De.mem Limited reported a net loss of $4.94 million for the financial year ending 30 June 2025.
- The company achieved a critical milestone with the successful delivery of a pivotal Phase III clinical trial for the Felix™ System in collaboration with Monash IVF.
- The Felix™ System demonstrated superiority in embryo utilisation rate and received a strong preference from embryologists.
- De.mem Limited submitted its CE Mark regulatory dossier for the Felix™ System in June 2025.
- Strategic advice suggests the CE Mark registration could take 6-12 months.
- The company is prioritizing direct sales of its Felix™ System, targeting early market deployment in countries with minimal regulatory requirements.
- Revenue from continuing ordinary activities decreased by 94% compared to the previous year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
